Free Trial

Neoleukin Therapeutics (NASDAQ:NLTX) Shares Up 6.3% - Should You Buy?

Neoleukin Therapeutics logo with Medical background

Key Points

  • Neoleukin Therapeutics (NASDAQ:NLTX) shares rose 6.3%, trading at $19.64, with an increased trading volume of 56,629 shares.
  • The company specializes in developing immunotherapies for cancer and related disorders, with its lead product candidate NL-201 aimed at treating various types of cancer.
  • Neoleukin Therapeutics has a market capitalization of $184.58 million and a price-to-earnings ratio of -6.32.
  • MarketBeat previews top five stocks to own in October.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report)'s stock price shot up 6.3% on Wednesday . The company traded as high as $19.83 and last traded at $19.64. 56,629 shares traded hands during mid-day trading, an increase of 13% from the average session volume of 50,104 shares. The stock had previously closed at $18.48.

Neoleukin Therapeutics Trading Up 6.3%

The firm has a 50-day simple moving average of $20.48 and a two-hundred day simple moving average of $17.37. The company has a market capitalization of $184.58 million, a price-to-earnings ratio of -6.32 and a beta of 1.11.

About Neoleukin Therapeutics

(Get Free Report)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Neoleukin Therapeutics Right Now?

Before you consider Neoleukin Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.

While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.